| 7.1 -0.6 (-7.79%) | 06-12 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 11.32  |
1-year : | 13.19 |
| Resists | First : | 9.69 |
Second : | 11.3 |
| Pivot price | 9.03 |
|||
| Supports | First : | 7.09 |
Second : | 5.9 |
| MAs | MA(5) : | 7.78 |
MA(20) : | 9.15 |
| MA(100) : | 9.39 |
MA(250) : | 10.98 |
|
| MACD | MACD : | -0.6 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 1.5 | D(3) : | 2.3 |
| RSI | RSI(14): 18.4 |
|||
| 52-week | High : | 18.39 | Low : | 7.07 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ EXOZ ] has closed below the lower bollinger band by 1.3%. If price is in a downtrend band; this downward trend might continue. However a short term pullback inside the band is likely. Bollinger Bands are 58% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 0 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 7.92 - 8 | 8 - 8.04 |
| Low: | 6.95 - 7.04 | 7.04 - 7.1 |
| Close: | 7 - 7.14 | 7.14 - 7.23 |
Operating within the United States, eXoZymes, Inc. is a pioneering synthetic biochemical enterprise. The company's primary innovation is SimplePath, a sophisticated platform engineered to synthesize a diverse spectrum of chemicals. This output encompasses essential pharmaceuticals, alternative fuels, advanced materials, food additives, and entirely new molecular entities. Integral to its design, the SimplePath platform incorporates distinct modules, each housing one or more enzymes that work synergistically to facilitate specific biocatalytic transformations. The firm was established in 2014 and maintains its corporate headquarters in Monrovia, California.
Tue, 09 Jun 2026
exozymes prices $5.3M public offering at $18 per unit By Investing.com - Investing.com Australia
Mon, 08 Jun 2026
eXoZymes (EXOZ) Prices Public Offering of Units - GuruFocus
Mon, 08 Jun 2026
eXoZymes Prices $18 Unit Equity Offering; MDB Capital Underwrites $5.33 Million Deal - TradingView
Mon, 08 Jun 2026
eXoZymes (NASDAQ: EXOZ) sells units in $5.3M underwritten offering - Stock Titan
Mon, 08 Jun 2026
eXoZymes Inc. Announces Pricing of Public Offering of Common Stock and Warrants - Newswire.com
Mon, 08 Jun 2026
AI enzyme firm eXoZymes prices $5.33M unit deal with resettable warrants - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 8 (M) |
| Shares Float | 6 (M) |
| Held by Insiders | 71.1 (%) |
| Held by Institutions | 0.7 (%) |
| Shares Short | 12 (K) |
| Shares Short P.Month | 12 (K) |
| EPS | -1.15 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.18 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -81.7 % |
| Return on Equity (ttm) | -185.9 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.17 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -7 (M) |
| Levered Free Cash Flow | -4 (M) |
| PE Ratio | -6.18 |
| PEG Ratio | 0 |
| Price to Book value | 39.44 |
| Price to Sales | 0 |
| Price to Cash Flow | -8.74 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|